SynthesisRheumatology (Oxford, England)2015
Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements.
Synthesis in Rheumatology (Oxford, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 141 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 6 syntheses or guidelines pooled it, 292 citations in OpenAlex.
- Sjögren's Syndrome and Ankylosing Spondylitis Association: A Case-Based Review.Current rheumatology reviews · 2025Pooled it
- Risk of dementia or Parkinson's disease in the presence of Sjögren's syndrome: A systematic review and meta-analysis.Frontiers in integrative neuroscience · 2022Pooled it
- Guideline
- Factors Associated With Renal Involvement in Primary Sjögren's Syndrome: A Meta-Analysis.Frontiers in medicine · 2020Pooled it
- A systematic review of primary Sjögren's syndrome in male and paediatric populations.Clinical rheumatology · 2017Pooled it
- Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2017Pooled it
- CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.Nature medicine · 2024Trial
- Efficacy and Safety of Acupuncture Combined with Hydroxychloroquine in Treating Primary Sjögren's Syndrome: A Randomized Controlled Trial.Chinese journal of integrative medicine · 2026Article
- Diagnostic performance of lung ultrasound B-lines and serum KL-6 in detecting Sjögren's disease-related interstitial lung diseases.Clinical rheumatology · 2026Article
- Clinicopathologic Features and Prognostic Factors in Biopsy-Confirmed Renal Involvement in Primary Sjőgren Syndrome.Kidney360 · 2026Article
- Anatomy of a Cohort: 40-Year Follow-Up of a Sjögren's Cohort.Journal of clinical medicine · 2026Article
- Article
- Sjogren's Disease-Aspects of Clinical Disease Beyond Dry Eyes/Mouth.Journal of clinical medicine · 2026Review
- The Role of Imaging Techniques in the Evaluation of Extraglandular Manifestations in Patients with Sjögren's Syndrome.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Clinical significance of radiological usual interstitial pneumonia pattern in primary Sjögren syndrome-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Clinical features, diagnosis, and treatment of primary Sjögren's disease with interstitial lung disease: A narrative review.Frontiers in immunology · 2026Review
- Risk of venous, arterial, and rare thrombotic events in adults with Sjögren's disease: a systematic review and meta-analysis.Reumatologia · 2026Review
- Clinical characteristics and risk factors for the bidirectional association between immune thrombocytopenia and Sjögren's syndrome.Clinical rheumatology · 2025Article
- Hypokalemic Quadriparesis as the Initial Presentation of Primary Sjögren's Syndrome With Distal Renal Tubular Acidosis: A Case Report.Clinical case reports · 2025Article
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 16 institutions in 8 countries.
Funding
Abstract
objectiveTo reach a European consensus on the definition and characterization of the main organ-specific extraglandular manifestations in primary SS.
methodsThe EULAR-SS Task Force Group steering committee agreed to approach SS-related systemic involvement according to the EULAR SS Disease Activity Index (ESSDAI) classification and proposed the preparation of four separate manuscripts: articular, cutaneous, pulmonary and renal ESSDAI involvement; muscular, peripheral nervous system, CNS and haematological ESSDAI involvement; organs not included in the ESSDAI classification; and lymphoproliferative disease. Currently available evidence was obtained by a systematic literature review focused on SS-related systemic features.
resultsThe following information was summarized for articular, cutaneous, pulmonary and renal involvement: a clear, consensual definition of the clinical feature, a brief epidemiological description including an estimate of the prevalence reported in the main clinical series and a brief list of the key clinical and diagnostic features that could help physicians clearly identify these features. Unfortunately we found that the body of evidence relied predominantly on information retrieved from individual cases, and the scientific information provided was heterogeneous. The analysis of types of involvement was biased due to the unbalanced reporting of severe cases over non-severe cases, although the main sources of bias were the heterogeneous definitions of organ involvement (or even the lack of definition in some studies) and the heterogeneous diagnostic approach used in studies to investigate involvment of each organ.
conclusionThe proposals included in this article are a first step to developing an optimal diagnostic approach to systemic involvement in primary SS and may pave the way for further development of evidence-based diagnostic and therapeutic guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.